Contact:Mary Oliveri
Phone:(434)924-9496
E-mail:mc7m@virginia.edu
UVa Health System, Department of Medicine, Hematology/Oncology seeks: Women ages 18 and older with metastatic breast cancer which has not responded to prior treatment with other types of specific chemotherapy medications for research study.
The purpose of this study is to see if the experimental drug called NKTR-102 is safe and effective in treating patients with breast cancer. This study will also look at how your cancer responds to the study medication. In addition, the study will look at the side effects of the study medication, and it will examine how long the study medication stays in your blood. The study involves blood draws, physical exams, pregnancy test, tests for heart function (electrocardiogram), CT/MRI scans and taking an experimental medicine. Depending on the study treatment you receive, your participation in this study will require approximately 17 or 26 study visits over one year. Each visit will last 3 to 4 hours. Your medical condition is followed every 3 months until completion of the study.
Study-related medications are provided free of charge.
Participant's insurance company will be billed for non-experimental medication, tests and procedures.
No compensation is provided for this study.
Contact Information:
For more information please contact:
" Mary Oliveri, CRC
" Tel: 434-924-9496 Email: mc7m@Virginia.EDU
" IRB-HSR # 14126 (Nektar 08-PIR-05)
Principal Investigator: Christiana Brenin, MD
|
|
Primary Investigator: Brenin Christiana,